NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
September 5, 2006 • Volume 3 / Number 34 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Gene Therapy Offers Treatment for Metastatic Melanoma

Director's Update
NCI Committed to Colorectal Cancer Prevention

Cancer Research Highlights
New Models of Breast Cancer Risk Focus on Breast Density

Celecoxib Significantly Reduces the Risk of Precancerous Colorectal Polyps

Overweight, Obesity in Midlife Increases Risk of Mortality

Suicidality Increased in Adult Survivors of Childhood Cancer

CCR Grand Rounds

Spotlight
After Avastin, Testing Theories about Blood Vessels and Cancer

Funding Opportunities

Featured Clinical Trial
Bevacizumab for Hormone-Refractory Prostate Cancer

Notes
NCI, FDA, Standards Institute to Collaborate on Nanotech Activities

New Members Appointed to DCLG

NCI Hosts Science Writers' Seminar on Cancer in Minority Populations

CCOP Profile
Upstate Carolina Community Clinical Oncology Program

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Notes

NCI, FDA, Standards Institute to Collaborate on Nanotech Activities
NCI, the Food and Drug Administration, and the National Institute of Standards and Technology recently announced an interagency Memorandum of Understanding (MOU) to collaborate on oncology-related issues in nanotechnology development for clinical benefit and the standardization of approaches for evaluating nanotechnology devices and materials for cancer diagnosis and treatment.

The goal of the MOU is to develop safe and effective cancer therapies using nanotechnology. The collaboration will focus primarily on the Nanotechnology Characterization Laboratory - which performs preclinical efficacy and toxicity testing of nanoparticles - by establishing a framework for effective risk identification, assessment, and evaluation of emerging nanotechnology products. The laboratory serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. Additional information is available at http://ncl.cancer.gov/index.asp.

New Members Appointed to DCLG
NCI Acting Director Dr. John Niederhuber has indicated his intent to appoint four new members to the NCI Director's Consumer Liaison Group (DCLG), NCI's only all-consumer advisory committee. The four new members, Dr. Grace L. Butler, Yvette Colón, Kelly L. Cotter, and Alan Kaye, would serve terms from 2006 through 2010. Two current members, Celeste Whitewolf and Margaret Anthony, have been reappointed for terms from 2006 through 2008. Dr. Niederhuber has also appointed current member Dr. Beverly Laird as DCLG vice chair and extended her term to 2008. Doug Ulman remains the chair. The DCLG charter has been renewed and the membership of the committee has been increased from 15 to 16 members. More information on DCLG is available at http://dclg.cancer.gov.

NCI Hosts Science Writers' Seminar on Cancer in Minority Populations
On September 6, from 1:00-3:00 p.m., NCI will host a Science Writers' Seminar on cancer rates in minority populations. The seminar will take place in the Natcher Conference Center, Room F1/F2, on the NIH campus in Bethesda, Md.

Topics will include the latest cancer statistics from the "Annual Report to the Nation," published that day in Cancer. In addition, four prominent scientists will explain how rates are changing in minority populations and what these trends mean for detecting and treating cancer effectively. Dr. Brenda Edwards of NCI will discuss perspectives on the "Annual Report to the Nation," Dr. Elmer Huerta of George Washington University will present information on cancer detection and prevention in Latino communities, Dr. Barry Miller of NCI will describe Latino cancer rates, and Dr. Grace Ma of Temple University will discuss acculturation in Asian American populations.

For additional information, contact the NCI Media Relations Branch at 301-496-6641 or ncipressofficers@mail.nih.gov.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov